Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06820723 · ClinicalTrials.gov registry record · Phase 2
A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety
A Phase 2 study, sponsored by Ohio State University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT06820723: Clinical Trial Phase 2 study, sponsored by Ohio State University.
NCT06820723 is a Phase 2 study that has not yet begun recruiting, run by Ohio State University. The registered enrollment target is 40 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06820723, a Phase 2 study, has not yet begun recruiting, sponsored by Ohio State University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The goal of this study is to learn how psychedelics may help symptoms of depression and anxiety. Participants with major depressive disorder experiencing symptoms of depression and anxiety will receive one dose of either a drug related to psilocybin or a placebo. Assessments include interviews, self-report questionnaires, EEG and fMRI to measure symptoms and brain function.
Primary Outcome
Change in Blood oxygenation level dependent (BOLD) fMRI signal after task comparing CYB003 group and placebo group
Interventions
- DRUG Placebo
- DRUG CYB003
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-11 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
What is known before NCT06820723 opens enrollment
NCT06820723 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06820723 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06820723 about?
NCT06820723 is a clinical study titled "A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety". The goal of this study is to learn how psychedelics may help symptoms of depression and anxiety. Participants with major depressive disorder experiencing symptoms of depression and anxiety will receive one dose of either a drug related to psilocybin or a placebo. Assessments include interviews, self...
What is the current status of trial NCT06820723?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-11. Estimated completion is 2027-11.
What interventions are being tested in trial NCT06820723?
The interventions under investigation include: Placebo (DRUG), CYB003 (DRUG).
Who is sponsoring clinical trial NCT06820723?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06820723's enrollment target sits among peer trials
40 1362nd of 2000 higher than 542 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia